Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP

Adherence to CPAP determines the expected benefits of the treatment. A dose-benefit relationship has been demonstrated for both functional and cardiovascular benefits. The first few days' use of the device are decisive in determining long-term compliance. In this context, daily monitoring of the data teletransmitted means that we can be more responsive to problems of compliance during the first few days of use; the contribution of telemonitoring can be very positive in a context of poor compliance.

In France, compulsory health insurance coverage of CPAP treatment is authorised for patients aged over 16 with clinical symptoms and an AHI ≥15 events per hour and <30 events/h in patients with severe cardiovascular co-morbidity. These patients are often not very sleepy due to sympathetic hypertonia with a shorter sleep duration. They are at high risk of non-compliance.

The IPIAM study specifically targets a population at cardiovascular risk and at high risk of non-compliance with CPAP treatment. The IPIAM study aims to involve patients in the success of their treatment via remote monitoring and to show that this approach makes it possible to improve the handling of alerts and to participate in the therapeutic support of the patient. Finally, this population also shares the risk of heart rhythm disorders. As part of a cross-disciplinary inter-pathology telemonitoring approach, it also makes sense to screen for cardiac rhythm disorders by wearing a connected watch.

Study Overview

• Status: Recruiting
• Conditions: OSA
• Intervention / Treatment: Device: New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application

Detailed Description

IPIAM is a prospective randomized controled study with two arms. Two approaches to telemonitoring will be compared: the standard telemonitoring carried out by the home healthcare provider (standard of care) will be compared with a new approach in which the patient is involved in managing his treatment by collecting vitals and notifying alerts via two connected devices (a connected watch and a mobile application).

The study will comprise 2 phases :

1. an initial interventional, comparative, randomised phase corresponding to the first 4 months of CPAP treatment,
2. an observational period with standard telemonitoring, lasting until the 12th month of treatment.

In this study, all patients will be treated with the same continuous positive airway pressure ventilator (AirSense 11 Autoset, ResMed).

CPAP alerts will be checked by the home healthcare provider's technicians every week and then managed differently depending on the randomisation group.

Each patient will be seen twice in pulmonology consultations, once for the inclusion visit and once 4 months after CPAP initation.

• Study Type: Interventional
• Enrollment (Estimated): 556
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Anne-Laure Sérandour; Phone Number: +33 2 99 12 19 62; Email: al.serandour@slbpharma.com
• Study Contact Backup: Name: Johan Dupuis; Phone Number: +33 7 89 20 75 33; Email: jdupuis@astensante.com

Study Locations

• France
  • Angers, France, 49100
    • Recruiting
    • CHU Angers - Service de pneumologie
    • Contact: Frédérique Gagnadoux, Pr
    • Principal Investigator: Frédérique Gagnadoux, Pr
    • Sub-Investigator: Wojciech Trzepizur, Pr
    • Sub-Investigator: Yasmina Pascaud-Mansour, Dr
    • Sub-Investigator: Caroline Marien, Dr
    • Sub-Investigator: Nicole Meslier, Dr
  • Dijon, France, 21000
    • Recruiting
    • CHU Dijon-Bourgogne
    • Contact: Pauline Sabot, Dr
    • Principal Investigator: Pauline Sabot, Dr
    • Sub-Investigator: Claudio Rabec, Dr
  • La Roche-sur-Yon, France, 85925
    • Recruiting
    • Ch Departemental Vendee
    • Contact: Acya Bizieux, Dr
    • Principal Investigator: Acya BIZIEUX, Dr
    • Sub-Investigator: Cyril GUIBERT, Dr
    • Sub-Investigator: Diane MAURE, Dr
    • Sub-Investigator: Elise REDUREAU, Dr
    • Sub-Investigator: Bastien SOUDET, Dr
  • Le Chesnay, France, 78150
    • Recruiting
    • CH Versailles
    • Contact: Alice De Sanctis, Dr
    • Principal Investigator: Alice De Sanctis, Dr
    • Sub-Investigator: Karine Gerold, Dr
  • Le Mans, France, 72037
    • Recruiting
    • CH Le mans
    • Contact: François Goupil, Dr
    • Principal Investigator: François Goupil, Dr
    • Sub-Investigator: Audrey Paris, Dr
    • Sub-Investigator: Marie Jouvenot, Dr
  • Nancy, France, 54511
    • Recruiting
    • CHU Nancy
    • Contact: Ari Chaouat, Pr
    • Sub-Investigator: Ari Chaouat, Pr
    • Principal Investigator: Bruno Ribeiro-Baptista, Dr
  • Paris, France, 75013
    • Recruiting
    • AP-HP Pitié Salpetrière
    • Principal Investigator: Maxime Patout, Dr
    • Sub-Investigator: Cécile Londner, Dr
    • Contact: Maxime Patout, Dr
    • Sub-Investigator: Valérie Attali, Dr
    • Sub-Investigator: Carole Philippe, Dr
    • Sub-Investigator: Clara Bianquis, Dr
  • Paris, France, 75018
    • Recruiting
    • AP-HP Bichat Claude Bernard
    • Contact: Marie-Pia D'Ortho, Pr
    • Principal Investigator: Marie-Pia D'Ortho, Pr
    • Sub-Investigator: Justine Frija-Masson, Dr
    • Sub-Investigator: Hélène Benzaquen, Dr
    • Sub-Investigator: Olivier Vernet, Dr
  • Paris, France, 75015
    • Recruiting
    • AP-HP Hôpital Européen Georges
    • Contact: Sven GÜNTHER, Dr
    • Principal Investigator: Sven GÜNTHER, Dr
    • Sub-Investigator: Adel ZADRI, Dr
  • Rennes, France, 35000
    • Recruiting
    • Polyclinique Saint-Laurent - Groupe médical de pneumologie
    • Contact: Arnaud Prigent, Dr
  • Rouen, France, 76000
    • Recruiting
    • CHU Rouen - Charles Nicolle
    • Contact: Marie-Anne Melone, Dr
    • Principal Investigator: Marie-Anne Melone, Dr
    • Sub-Investigator: Antoine Cuvelier, Pr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult with newly diagnosed OSA (with central apnea index <5 ev/h), justifying CPAP and with low sleepiness (Epworth score <11 at inclusion).
• Patient with at least 1 cardiovascular risk factor (obesity, type I or II diabetes with or without treatment, permanent hypertension with or without treatment, heart failure with preserved ejection fraction, valve disease, history of atrial fibrillation, history of ischaemic heart disease, history of stroke).
• Patient with a smartphone and who agrees to use connected objects during the study.
• Signed informed consent form,
• Subject affiliated to a health insurance system, or is a beneficiary.

Exclusion Criteria:

• Patients already fitted with a CPAP machine,
• Patients with permanent atrial fibrillation,
• Patients whose state of health is not stable or requires heavy treatment,
• Patients with cognitive problems.
• Patients participating in another intervention research in pulmonology.
• Vulnerable subject

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard CPAP telemonitoring; Patients are treated with CPAP and the home healthcare provider carries out monitoring in line with current practice (telemonitoring of treatment and regular home visits).
Experimental: New CPAP telemonitoring approach; Patients are treated with CPAP and the home healthcare provider is offering a new approach to remote monitoring in which patients are involved in managing their CPAP treatment using two connected devices (the Scanwatch connected watch + the mobile application Asten&masanté) in the first 4 months of treatment.	Device: New telemonitoring approach using 2 connected devices : Scanwatch connected watch + Asten&masanté application; The home healthcare provider will monitor the treatment remotely and make home visits, as in the control group. However, in the case of technical alerts concerning CPAP treatment (problems with observance, leaks, residual apneas), the provider will send the patient a notification via the mobile application in order to provide advice/instructions so that the patient can resolve the alert independently. The provider will monitor the resolution of alerts remotely and may contact the patient by telephone or come to your home if necessary. If the connected watch detects an abnormal heart rhythm at night, the patient receives a notification and can undergo an electrocardiogram.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CPAP treatment adherence	Measurement of the average daily duration of use of the CPAP (expressed in hours) over the last 30 nights, 4 months after initiation of treatment. The duration of use will be compared between both groups.	Month 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of CPAP treatment assessed by leaks	Measurement of the average leaks (expressed in liter per minute) per month using the daily data teletransmitted by CPAP ventilator throughout the follow-up period.	Month 1, Month 2, Month 3, Month 4
Quality of CPAP treatment assessed by apnea hypopnea index	Measurement of the average residual apnea hypopnea index (expressed in number of event per hour) per month using the daily data teletransmitted by CPAP ventilator throughout the follow-up period.	Month 1, Month 2, Month 3, Month 4
long term CPAP treatment adherence	Measurement of the average daily duration of use of the CPAP (expressed in hours) over the last 30 nights, 6 months and 1 year after initiation of treatment.	Month 6, Year 1
Number of nights with Cheynes Stoke Respirations (CSR)	Average number of nights with CSR per patient per 30-day period during the first 4 months of treatment.	over the first 4 months
Nocturnal heart rate	Night-time heart rate teletransmitted daily by the connected watch during the first 4 months, only in the experimental group.	over the first 4 months
Number of alerts	Average number of technical and medical alerts (related to adherence, leaks, apnea, CSR, increase in heart rate, atrial fibrillation) per patient per 30-day period during the first 4 months of treatment.	over the first 4 months
Number of medical events (pneumology and cardiology consultations, hospitalizations) related to OSA	Average number of medical events (pneumology and cardiology consultations, hospitalizations) related to OSA per patient	Month 4
F-SUS questionnaire	The French System Usability Scale (SUS) is a questionnaire evaluating the patient satisfaction on usability of interactive systems. The questionnaire comprises 10 questions and the score of user satisfaction varies from 0 to 100 (0 lowest score; 100 highest score).	Month 4
Number of home healthcare provider interventions	Average number of home healthcare provider interventions (phone call, home visit, remote assistance) per patient.	over the first 4 months

Collaborators and Investigators

• Sponsor: Asten Sante
• Collaborators: Slb Pharma; Withings; Nouvéal
• Investigators: Principal Investigator: Arnaud Prigent, Dr, Polyclinique Saint-Laurent

Study record dates

Study Major Dates

• Study Start (Actual): September 29, 2023
• Primary Completion (Estimated): January 31, 2026
• Study Completion (Estimated): October 30, 2026

Study Registration Dates

• First Submitted: July 11, 2023
• First Submitted That Met QC Criteria: July 21, 2023
• First Posted (Actual): July 25, 2023

Study Record Updates

• Last Update Posted (Actual): August 11, 2025
• Last Update Submitted That Met QC Criteria: August 6, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Telemedicine; OSA; Continuous positive airway pressure (CPAP); Cheyne-Stokes respiration (CSR)
• Other Study ID Numbers: IPIAM

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No